Oncology

Back to articles

Promising therapies for metastatic melanoma

KEY POINT

Results from two studies evaluating investigational agents for the treatment of metastatic melanoma, one with ipilimumab (Bristol-Myers Squibb) and the other with PLX4032 (Plexxikon; Roche), showed that ipilimumab improved overall survival in patients exposed to previous treatments and that PLX4032 resulted in complete or partial tumor regression in a small number of patients who carry the V600E BRAF mutation.

SOURCES

Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

Hwu P. Treating cancer by targeting the immune system. N Engl J Med. 2010;363:779–81.

Flaherty KT et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19.

Smalley KSM, Sondak VK. Melanoma—an unlikely poster child for personalized cancer therapy. N Engl J Med. 2010;363:876–8.